Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Gene Therapy for Glaucoma by Ciliary Body Aquaporin 1 Disruption Using CRISPR-Cas9

10 Jan 2020

Abstract excerpt

Glaucoma is a common cause of blindness, yet current therapeutic options are imperfect. Clinical trials have invariably shown that reduction in intraocular pressure (IOP) regardless of disease subtype prevents visual loss. Reducing ciliary body aqueous humor production can lower IOP, and the adeno-associated virus ShH10 serotype was identified as able to transduce mouse ciliary body epithelium following...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CRISPR and Genetic Engineering
Share to Retinal Development and Disorders
Share to Retinopathy of Prematurity Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31981492
DOI: 10.1016/j.ymthe.2019.12.012

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Gene Therapy for Glaucoma by Ciliary Body Aquaporin 1 Disruption Using CRISPR-Cas9PMID 31981492Read ↗

Gene therapy for ocular hypertension using hfCas13d-mediated mRNA targetingSemantic proximity Read ↗

CRISPR-Cas9-mediated deletion of carbonic anhydrase 2 in the ciliary body to treat glaucomaSemantic proximity Read ↗

CRISPR-CasRx-mediated disruption of Aqp1/Adrb2/Rock1/Rock2 genes reduces intraocular pressure and retinal ganglion cell damage in miceSemantic proximity Read ↗

Gene Therapy in the Anterior Eye SegmentSemantic proximity Read ↗

Glaucoma, Stem Cells, and Gene Therapy: Where Are We Now?Semantic proximity Read ↗

Using CRISPR Interference as a Therapeutic Approach to Treat TGFβ2-Induced Ocular Hypertension and GlaucomaSemantic proximity Read ↗

Ocular delivery of CRISPR/Cas genome editing components for treatment of eye diseasesSemantic proximity Read ↗

CRISPR-Cas9–based treatment of myocilin-associated glaucomaSemantic proximity Read ↗

Genetic and Functional Characterization of ANGPTL7 as a Therapeutic Target for GlaucomaSemantic proximity Read ↗

Inducible scAAV2.GRE.MMP1 lowers IOP long-term in a large animal model for steroid-induced glaucoma gene therapySemantic proximity Read ↗

Cell Atlas of Aqueous Humor Outflow Pathways in Eyes of Humans and Four Model Species Provides Insights into Glaucoma PathogenesisSemantic proximity Read ↗

Lentiviral mediated delivery of CRISPR/Cas9 reduces intraocular pressure in a mouse model of myocilin glaucomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.